Literature DB >> 193086

Auditory and visual defects resulting from symptomatic and subclinical congenital cytomegaloviral and toxoplasma infections.

S Stagno, D W Reynolds, C S Amos, A J Dahle, F P McCollister, I Mohindra, R Ermocilla, C A Alford.   

Abstract

Sensorineural hearing loss was present in ten of 59 (17%) patients with congenital cytomegalovirus (CMV) infection (three of eight born with symptomatic and seven of 51 born with subclinical infection). The defect was bilateral in eight, moderate to profound in eight, and of progressive nature in two. Hearing loss did not occur in 21 patients with natal CMV infection nor in seven of 12 patients with congenital toxoplasmosis. Histopathologic and immunofluorescent studies of the inner ear in two of three neonates who died with severe infection revealed that viral antigens were widely distributed in cochlear structures. Eye pathology was associated only with congenital Toxoplasma (nine of 12) and CMV (seven of 43) infections. Visual impairments were more prominent and severe in those born with symptomatic infections, exclusively so with CMV. However, ocular defects, in particular chorioretinitis, developed after birth in five of eight patients born with asymptomatic congenital toxoplasmosis. These data firmly establish clinically inapparent congenital CMV infection as a major public health problem and confirm the fact that congenital toxoplasmosis may be associated with late-appearing, debilitating chorioretinitis.

Entities:  

Mesh:

Year:  1977        PMID: 193086

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  38 in total

1.  Should active CMV retinitis in non-immunocompromised newborn babies be treated?

Authors:  F Barampouti; M Rajan; W Aclimandos
Journal:  Br J Ophthalmol       Date:  2002-02       Impact factor: 4.638

2.  Congenital cytomegalovirus infection: a cause of sensorineural hearing loss.

Authors:  C S Peckham; O Stark; J A Dudgeon; J A Martin; G Hawkins
Journal:  Arch Dis Child       Date:  1987-12       Impact factor: 3.791

3.  Confirmation of human cytomegalovirus by reverse passive hemagglutination with monoclonal antibodies reactive to the major glycosylated peptide (GP-66).

Authors:  K S Kim; V Sapienza; C M Chen
Journal:  J Clin Microbiol       Date:  1986-09       Impact factor: 5.948

Review 4.  The murine cytomegalovirus as a model for the study of viral pathogenesis and persistent infections.

Authors:  J B Hudson
Journal:  Arch Virol       Date:  1979       Impact factor: 2.574

Review 5.  Congenital and infantile cataract: aetiology and management.

Authors:  Wai H Chan; Susmito Biswas; Jane L Ashworth; I Christopher Lloyd
Journal:  Eur J Pediatr       Date:  2012-03-01       Impact factor: 3.183

Review 6.  Treatment of congenital cytomegalovirus infection: implications for future therapeutic strategies.

Authors:  Lauren Nassetta; David Kimberlin; Richard Whitley
Journal:  J Antimicrob Chemother       Date:  2009-03-14       Impact factor: 5.790

7.  Rehabilitation and outcome of severe profound deafness in a group of 16 infants affected by congenital cytomegalovirus infection.

Authors:  Andrea Ciorba; Roberto Bovo; Patrizia Trevisi; Chiara Bianchini; Rosa Arboretti; Alessandro Martini
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-03-13       Impact factor: 2.503

8.  Cytomegalovirus-infected cell polypeptides immune-precipitated by sera from children with congenital and perinatal infections.

Authors:  L Pereira; S Stagno; M Hoffman; J E Volanakis
Journal:  Infect Immun       Date:  1983-01       Impact factor: 3.441

9.  Immune complexes in congenital and natal cytomegalovirus infections of man.

Authors:  S Stagno; J E Volanakis; D W Reynolds; R Stroud; C A Alford
Journal:  J Clin Invest       Date:  1977-10       Impact factor: 14.808

10.  Microphthalmia and cerebral atrophy induced in mouse embryos by infection with murine cytomegalovirus in midgestation.

Authors:  Y Tsutsui; A Kashiwai; N Kawamura; C Kadota
Journal:  Am J Pathol       Date:  1993-09       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.